The Senate Health & Human Services Committee heard testimony on SB 26-031, a bill that would automatically align Colorado's drug scheduling with federal FDA/DEA classifications for newly approved medications, with no vote taken — the bill was laid over for action only at the sponsor's request, with the chair noting action will hopefully be heard in the near future in committee.
“A new drug class has not been approved for anxiety. Get this in over 20 years as we work to expand mental health care.”
+ 4 more quotes
Subscribe to see all key actions, controversies, quotes, and what's next.
Sign in to subscribeSenate Health and Human Services Committee will come to order. Mr. Brown, please call the roll. Senators Bright. Good morning. Carson. Excused. Utter. Present. Doherty. Excused. Grizzell. Essent. Judah Weissman. Good morning. Michaelson. Janae essent. Mr. Jar Malika. Here. Members, we do have a bill, Senate Bill 31 before us. We just for the committee's knowledge, we're going to take testimony on this bill today. But at the sponsor's request, we're going to lay this over for action only so that there can be, I think, a little bit more work done on it. But we did want to get testimony done today as this was on the calendar and so we have both of our sponsors here who would like to start us off. Madam Vice Chair. Thank you, Mr. Chair. Thank you members for hearing this bill today. The the goal of the bill is to expand anxiety and mental health medications through the use of FDA approved psychedelics. Mental health is a striking and growing issue within the United States, including 60 million adults affected by mental illness. Among these diagnoses include generalized anxiety disorder, depression and ptsd, which can affect vulnerable population such as veterans. Current…
Subscribe to unlock the full transcript, summary, and search across all Colorado committee hearings.
Sign in to subscribe